Patents by Inventor Yves Pommier
Yves Pommier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240002445Abstract: Disclosed is a class of knotted cyclic peptides. Related pharmaceutical compositions and methods of using the peptides and methods of synthesizing the peptides are also disclosed.Type: ApplicationFiled: November 17, 2021Publication date: January 4, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Barry R. O'Keefe, Lauren R. Haugh Krumpe, Yves Pommier, Christophe R. Marchand, Ingrid C. Schroeder, K. Johan Rosengren, Brice A.P. Wilson
-
Publication number: 20210220329Abstract: The disclosure provides a method of treating triple negative breast cancer in a patient, comprising administering a therapeutically effective amount of a compound selected from oxyphenisatin, oxyphenisatin acetate, and bisacodyl, or the pharmaceutically acceptable salts or hydrates of any of the foregoing to the patient. The disclosure also provides methods of using oxyphenisatin or bisacodyl, or a salt or hydrate thereof, as a first active agent in combination with one or more additional active agents to treat triple negative breast cancer. The disclosure further provides methods for determining whether a patient suffering from triple negative breast cancer would be responsive to treatment with oxyphenisatin or bisacodyl.Type: ApplicationFiled: February 8, 2019Publication date: July 22, 2021Inventors: William Curtis Reinhold, Mathew Garnett, Vinodh Nalin Rajapakse, Yves Pommier, Augustin Luna
-
Publication number: 20210139492Abstract: Compounds of Formula I and the pharmaceutically acceptable salts thereof are disclosed The variables X1, X2, and R1-4 are disclosed herein. The compounds are useful for treating cancer and related proliferative diseases. Pharmaceutical compositions containing compounds of Formula I and methods of treatment comprising administering compounds of Formula I are also disclosed.Type: ApplicationFiled: January 11, 2021Publication date: May 13, 2021Inventors: Linkun An, Christophe Marchand, Yves Pommier
-
Patent number: 10906914Abstract: Compounds of Formula I and the pharmaceutically acceptable salts thereof are disclosed Formula I. The variables X1, X2, and R1-4 are disclosed herein. The compounds are useful for treating cancer and related proliferative diseases. Pharmaceutical compositions containing compounds of Formula I and methods of treatment comprising administering compounds of Formula I are also disclosed.Type: GrantFiled: January 8, 2016Date of Patent: February 2, 2021Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, SUN YAT-SEN UNIVERSITYInventors: Linkun An, Christophe Marchand, Yves Pommier
-
Patent number: 10759795Abstract: The invention described herein pertains to four series of aza-A-ring indenoisoquinolines, which are inhibitors of topoisomerase IB (Top1), and the processes for preparing said aza-A-ring indenoisoquinolines. Also described are methods for treating cancer in mammals using the described aza-A-ring indenoisoquinoline compounds or pharmaceutical formulations thereof.Type: GrantFiled: March 15, 2017Date of Patent: September 1, 2020Assignees: PURDUE RESEARCH FOUNDATION, UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Mark S. Cushman, Daniel E. Beck, Yves Pommier
-
Patent number: 10617706Abstract: The invention provides a compound of formula (I), (II) or (III): wherein R1, R2, R3, R4 and R5 have any of the values described in the specification, as well as compositions comprising a compound of formula (I), (II) or (III). The compounds and compositions are useful as chemotherapeutic sensitizing agents.Type: GrantFiled: February 4, 2019Date of Patent: April 14, 2020Assignees: REGENTS OF THE UNIVERSITY OF MINNESOTA, THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICESInventors: Zhengqiang Wang, Jayakanth Kankanala, Yves Pommier
-
Publication number: 20190382401Abstract: The invention described herein pertains to four series of aza-A-ring indenoisoquinolines, which are inhibitors of topoisomerase IB (Top1), and the processes for preparing said aza-A-ring indenoisoquinolines. Also described are methods for treating cancer in mammals using the described aza-A-ring indenoisoquinoline compounds or pharmaceutical formulations thereof.Type: ApplicationFiled: March 15, 2017Publication date: December 19, 2019Applicant: Purdue Research FoundationInventors: Mark S. CUSHMAN, Daniel E. BECK, Yves POMMIER
-
Publication number: 20190240244Abstract: The invention provides a compound of formula (I), (II) or (III): wherein R1, R2, R3, R4 and R5 have any of the values described in the specification, as well as compositions comprising a compound of formula (I), (II) or (III). The compounds and compositions are useful as chemotherapeutic sensitizing agents.Type: ApplicationFiled: February 4, 2019Publication date: August 8, 2019Inventors: Zhengqiang Wang, Jayakanth Kankanala, Yves Pommier
-
Patent number: 10208035Abstract: A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is N, C(OH), or CH; Y is H or OH; each of Z1-Z5 is independently H or halogen; R4 is H, OH, NH2, NHR8, NR8R9 or R8; R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and R8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen tType: GrantFiled: May 8, 2017Date of Patent: February 19, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Xue Zhi Zhao, Steven Smith, Mathieu Metifiot, Barry Johnson, Christophe Marchand, Stephen H. Hughes, Yves Pommier, Terrence R. Burke, Jr.
-
Publication number: 20180009822Abstract: Compounds of Formula I and the pharmaceutically acceptable salts thereof are disclosed Formula I. The variables X1, X2, and R1-4 are disclosed herein. The compounds are useful for treating cancer and related proliferative diseases. Pharmaceutical compositions containing compounds of Formula I and methods of treatment comprising administering compounds of Formula I are also disclosed.Type: ApplicationFiled: January 8, 2016Publication date: January 11, 2018Inventors: Linkun An, Christophe Marchand, Yves Pommier
-
Publication number: 20170305904Abstract: A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is N, C(OH), or CH; Y is H or OH; each of Z1-Z5 is independently H or halogen; R4 is H, OH, NH2, NHR8, NR8R9 or R8; R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and R8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen tType: ApplicationFiled: May 8, 2017Publication date: October 26, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Xue Zhi Zhao, Steven Smith, Mathieu Metifiot, Barry Johnson, Christophe Marchand, Stephen H. Hughes, Yves Pommier, Terrence R. Burke, JR.
-
Patent number: 9676771Abstract: A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is N, C(OH), or CH; Y is H or OH; each of Z1-Z5 is independently H or halogen; R4 is H, OH, NH2, NHR8, NR8R9 or R8; R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and R8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen tType: GrantFiled: May 13, 2014Date of Patent: June 13, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Xue Zhi Zhao, Steven Smith, Mathieu Metifiot, Barry Johnson, Christophe Marchand, Stephen H. Hughes, Yves Pommier, Terrence R. Burke, Jr.
-
Publication number: 20160083382Abstract: A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is N, C(OH), or CH; Y is H or OH; each of Z1-Z5 is independently H or halogen; R4 is H, OH, NH2, NHR8, NR8R9 or R8; R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and R8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen tType: ApplicationFiled: May 13, 2014Publication date: March 24, 2016Applicant: The United States of American, as represented by the Sec, Dept. of Health and Human ServicesInventors: Xue Zhi Zhao, Steven Smith, Mathieu Metifiot, Barry Johnson, Christophe Marchand, Stephen H. Hughes, Yves Pommier, Terrence R. Burke, Jr.
-
Patent number: 9278089Abstract: A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: G1 is a group of the formula or where n is 0, 1, 2, 3, or 4 and Het is a 5- or 6-membered heteroaryl group containing 1 to 4 heteroatoms independently chosen from N, O, and S, which Het is optionally substituted.Type: GrantFiled: October 26, 2012Date of Patent: March 8, 2016Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: David Waugh, Christopher Self, Guangtao Zhang, Yves Pommier, Robert H. Shoemaker, Michael Currens, John Cardellina, Andrew Jobson, George Lountos, Dominic Scudiero
-
Publication number: 20150218120Abstract: Provided herein, inter alia, are novel compounds for the inhibition of HIV integrase. The compounds disclosed herein are useful for methods of treating HIV infection in a subject in need thereof.Type: ApplicationFiled: February 5, 2015Publication date: August 6, 2015Inventors: Seth M. Cohen, Arpita Agrawal, Jamie DeSoto, Yves Pommier, Kasthuraiah Maddali
-
Patent number: 8912214Abstract: Described herein are Chk2-inhibitor compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.Type: GrantFiled: July 27, 2006Date of Patent: December 16, 2014Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Yves Pommier, Robert H. Shoemaker, Dominic Scudiero, Michael Currens, John Cardellina, Andrew Jobson
-
Patent number: 8865686Abstract: The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders.Type: GrantFiled: September 29, 2008Date of Patent: October 21, 2014Assignee: The United States of America, as Represented by the Secretary, Dept. of Health and Human ServicesInventors: Yves Pommier, Laurent Thibaut, Christophe Marchand
-
Publication number: 20140294767Abstract: A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: G1 is a group of the formula or where n is 0, 1, 2, 3, or 4 and Het is a 5- or 6-membered heteroaryl group containing 1 to 4 heteroatoms independently chosen from N, O, and S, which Het is optionally substituted.Type: ApplicationFiled: October 26, 2012Publication date: October 2, 2014Inventors: David Waugh, Christopher Self, Guangtao Zhang, Yves Pommier, Robert H. Shoemaker, Michael Currens, John Cardellina, Andrew Jobson, George Lountos, Dominic Scudiero
-
Patent number: 8765802Abstract: Provided herein are Compounds having the following structure: wherein A, L, X and ring B are as defined herein, compositions comprising an effective amount of a Compound and methods for treating or preventing cancer, hypoxia, diabetes, stroke, autoimmune disease or a condition treatable or preventable by inhibition of Chk2, the ATM-Chk2 pathway or RSK2 comprising administering an effective amount of a Compound to a patient in need thereof.Type: GrantFiled: June 9, 2008Date of Patent: July 1, 2014Assignees: Provid Pharmaceuticals, Inc., United States of America as represented by the Department of Health and Human Resources NIHInventors: Robert Shoemaker, John Cardellina, Michael Currens, Sudhir Kondapaka, Yves Pommier, Andy Jobson, Dominic Scudiero, David Waugh, George Lountos, Guangtao Zhang, Andrew Colasanti, Christopher R. Self, Janet Cicariello Cook
-
Publication number: 20140142137Abstract: Provided herein, inter alia, are novel compounds for the inhibition of HIV integrase. The compounds disclosed herein are useful for methods of treating HIV infection in a subject in need thereof.Type: ApplicationFiled: August 2, 2013Publication date: May 22, 2014Applicants: National Institutes of Health, The Regents of the University of CaliforniaInventors: Seth M. Cohen, Arpita Agrawal, Jamie DeSoto, Yves Pommier, Kasthuraiah Maddali